J.B.CHEMICALS & PHARMACEUTICALS LTD.

JB Chemicals & Pharmaceuticals Ltd dispatched letters with web-links to access the Integrated Annual Report for FY 2025-26 to shareholders who haven't registered their email addresses with the Registrar & Share Transfer Agent or Depository Participants. The 50th Annual General Meeting (AGM) is scheduled for June 17, 2026, via Video Conference. The AGM notice and Integrated Annual Report have been sent electronically to members with registered email addresses.

JB Chemicals & Pharmaceuticals Ltd has released its Integrated Annual Report for the fiscal year 2025-26, in compliance with SEBI regulations. The report, along with the notice for the Annual General Meeting scheduled for June 17, 2026, will be sent to the company's shareholders. The annual report highlights the company's legacy, sustainable growth, financial performance, and strategic focus on strengthening its domestic franchise and expanding its international presence. JB Pharma has a presence in 40+ countries with 8 manufacturing facilities.

JB Chemicals & Pharmaceuticals Ltd has announced that its Annual General Meeting (AGM) will be held on June 17, 2026, at 3:00 p.m. (IST) via video conferencing. The meeting will cover the adoption of audited financial statements for the year ended March 31, 2026, confirmation of an interim dividend of ₹12.70 per share, declaration of a final dividend of ₹9.30 per share, and the re-appointment of Mr. Amal Kelshikar as a director.

JB Chemicals & Pharmaceuticals Ltd has fixed May 29, 2026, as the record date to determine the eligibility of shareholders for the final dividend for the financial year 2025-26. This decision was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has requested the exchange to take note of this intimation.

JB Chemicals & Pharmaceuticals Ltd's Board of Directors has recommended a final dividend of ₹9.30 (930%) per share with a face value of Re. 1 for the financial year 2025-26. The dividend, if approved by shareholders at the upcoming Annual General Meeting, will be distributed within 30 days of declaration. The board meeting to consider the dividend commenced at 6:15 p.m. and concluded at 6:56 p.m.

JB Chemicals & Pharmaceuticals Ltd announced its FY26 results. Revenue reached ₹4,148 crores, a 6% YoY increase. Net profit after tax stood at ₹709 crores, up 8% YoY. Q4 FY26 revenue was ₹904 crores, with a net profit of ₹101 crores. The company experienced a muted performance in Q4 due to operational resets and integration activities following a change of control, but expects recovery in H1. India business grew by 9% for FY26, while international formulations saw a 2% increase.

JB Chemicals & Pharmaceuticals Ltd. has announced its audited standalone and consolidated financial results for the year ended March 31, 2026. The results, along with the auditor's report by Deloitte Haskins & Sells LLP, were approved by the Board of Directors in a meeting held on the same day. The board also declared an unmodified opinion on the audited financial results. The company stated that disclosures regarding deviation/variation in public issue proceeds and outstanding loan defaults are not applicable for the quarter ended March 31, 2026.

JB Chemicals & Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 11, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend on equity shares for FY 2025-26, subject to shareholder approval.

JB Chemicals & Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the securities of the company. The closure will be in effect from April 1, 2026 until 48 hours after the declaration of the audited financial results for the quarter and year ending on March 31, 2026 by the Board of Directors. This decision comes in accordance with the company's code of conduct framed under the SEBI (Prohibition of Insider Trading) Regulations.

JB Chemicals & Pharmaceuticals Ltd. has announced a meeting of equity shareholders to consider and approve the proposed Scheme of Amalgamation with Torrent Pharmaceuticals Ltd. The meeting is scheduled for April 28, 2026, at 2:00 p.m. (IST) through Video Conferencing / Other Audio-Visual Means. The Notice of the meeting, Explanatory Statement, Scheme of Amalgamation, Financial Statements, and various reports are available on the company's website. The remote e-voting will be available from April 24, 2026, to April 27, 2026, and e-voting at the meeting will be available for those Equity Shareholders who had not voted through remote e-voting.